Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Idelalisib + Naratuximab emtansine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Idelalisib | Zydelig | CAL-101|GS-1101 | PIK3CD inhibitor 27 | Zydelig (idelalisib) inhibits PI3K-delta, preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival (PMID: 24450857). Zydelig (idelalisib) in combination with Rituxan (rituximab) is FDA-approved for use in patients with relapsed chronic lymphocytic leukemia (FDA.gov). |
| Naratuximab emtansine | IMGN 529|Debio 1562|IMGN529 | CD37 Antibody 9 | Naratuximab emtansine (IMGN529) is an antibody-drug conjugate consisting of a humanized anti-CD37 monoclonal antibody linked to the anti-mitotic agent, maytansinoid DM1, thereby inducing cell death of B-cells expressing CD37 (PMID: 29453628, PMID: 28753442). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|